TY - JOUR
T1 - Treatment strategies in myelodysplastic syndromes
AU - Atallah, Ehab
AU - Garcia-Manero, Guillermo
N1 - Funding Information:
Keywords: 5-Azacytidine, 5-Aza-2′-deoxycytidine, Lenalidomide, DNA methylation, Myelodysplastic syndromes. Supported in part by a Physician-Scientist Award from the Commonwealth Cancer Foundation for Research, the Leukemia and Lymphoma Society of America and NCI grant CA105771 (All to G G-M) and NCI grant 5P01 CA108631. Correspondence to: Guillermo Garcia-Manero Department of Leukemia Box 428 University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Houston TX 77030 tel: 713 745 3428; fax: 713 794 4297 email: ggarciam@mdanderson.org
PY - 2008/2
Y1 - 2008/2
N2 - Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2′- deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.
AB - Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2′- deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.
KW - 5-Aza-2′-deoxycytidine
KW - 5-Azacytidine
KW - DNA methylation
KW - Lenalidomide
KW - Myelodysplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=38949120072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38949120072&partnerID=8YFLogxK
U2 - 10.1080/07357900701788122
DO - 10.1080/07357900701788122
M3 - Review article
C2 - 18259954
AN - SCOPUS:38949120072
SN - 0735-7907
VL - 26
SP - 208
EP - 216
JO - Cancer Investigation
JF - Cancer Investigation
IS - 2
ER -